Trevena Shares Jump On Study Of 'tummy Tuck' Pain Treatment

Shares of Trevena Inc. jumped in the extended session Monday after the drug developer announced positive results for its post-surgery pain treatment. Trevena shares surged 33% to $8. The company said a mid-stage clinical trial for its drug candidate TRV130 showed the treatment was statistically more effective at treating moderate to severe pain in patients following abdominoplasty surgery, or what is more popularly known as a "tummy tuck."